NASDAQ: GLSI
Greenwich Lifesciences Inc Stock Forecast, Predictions & Price Target

Analyst price target for GLSI

Based on 1 analyst offering 12 month price targets for Greenwich Lifesciences Inc

Min Forecast
$39.00+237.95%
Avg Forecast
$39.00+237.95%
Max Forecast
$39.00+237.95%

Should I buy or sell GLSI stock?

Based on 1 analyst offering ratings for Greenwich Lifesciences Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although GLSI's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates GLSI as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their GLSI stock forecasts and price targets.

GLSI stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-21

1 of 1

Forecast return on equity

Is GLSI forecast to generate an efficient return?

Company
3,768.58%
Industry
127.94%
Market
-56.15%
GLSI's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is GLSI forecast to generate an efficient return on assets?

Company
1,735.89%
Industry
47.15%
GLSI is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

GLSI earnings per share forecast

What is GLSI's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$1.10
Avg 2 year Forecast
-$1.48
Avg 3 year Forecast
-$1.47

GLSI revenue forecast

What is GLSI's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$8.8M
Avg 2 year Forecast
$140.0M
Avg 3 year Forecast
$310.6M

GLSI vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GLSI$11.54$39.00+237.95%Buy
MCRB$18.03$6.00-66.72%Hold
AVTX$11.88$24.75+108.33%Strong Buy
TVGN$0.82$10.00+1,116.55%Strong Buy
ELDN$2.55$9.00+252.94%Buy

Greenwich Lifesciences Stock Forecast FAQ

Is Greenwich Lifesciences Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: GLSI) stock is to Buy GLSI stock.

Out of 1 analyst, 0 (0%) are recommending GLSI as a Strong Buy, 1 (100%) are recommending GLSI as a Buy, 0 (0%) are recommending GLSI as a Hold, 0 (0%) are recommending GLSI as a Sell, and 0 (0%) are recommending GLSI as a Strong Sell.

If you're new to stock investing, here's how to buy Greenwich Lifesciences stock.

What is GLSI's earnings growth forecast for 2025-2027?

(NASDAQ: GLSI) Greenwich Lifesciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.1%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.23%.

Greenwich Lifesciences's earnings in 2025 is -$17,992,572.On average, 2 Wall Street analysts forecast GLSI's earnings for 2025 to be -$14,925,131, with the lowest GLSI earnings forecast at -$17,037,821, and the highest GLSI earnings forecast at -$12,812,442. On average, 1 Wall Street analyst forecast GLSI's earnings for 2026 to be -$20,172,780, with the lowest GLSI earnings forecast at -$20,172,780, and the highest GLSI earnings forecast at -$20,172,780.

In 2027, GLSI is forecast to generate -$20,036,478 in earnings, with the lowest earnings forecast at -$20,036,478 and the highest earnings forecast at -$20,036,478.

What is GLSI's revenue growth forecast for 2027-2029?

(NASDAQ: GLSI) Greenwich Lifesciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 81.68%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.86%.

Greenwich Lifesciences's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast GLSI's revenue for 2027 to be $119,264,749, with the lowest GLSI revenue forecast at $119,264,749, and the highest GLSI revenue forecast at $119,264,749. On average, 1 Wall Street analysts forecast GLSI's revenue for 2028 to be $1,908,235,980, with the lowest GLSI revenue forecast at $1,908,235,980, and the highest GLSI revenue forecast at $1,908,235,980.

In 2029, GLSI is forecast to generate $4,233,898,581 in revenue, with the lowest revenue forecast at $4,233,898,581 and the highest revenue forecast at $4,233,898,581.

What is GLSI's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: GLSI) forecast ROA is 1,735.89%, which is higher than the forecast US Biotechnology industry average of 47.15%.

What is GLSI's Price Target?

According to 1 Wall Street analyst that have issued a 1 year GLSI price target, the average GLSI price target is $39.00, with the highest GLSI stock price forecast at $39.00 and the lowest GLSI stock price forecast at $39.00.

The Wall Street analyst predicted that Greenwich Lifesciences's share price could reach $39.00 by Apr 21, 2026. The average Greenwich Lifesciences stock price prediction forecasts a potential upside of 237.95% from the current GLSI share price of $11.54.

What is GLSI's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: GLSI) Greenwich Lifesciences's current Earnings Per Share (EPS) is -$1.36. On average, analysts forecast that GLSI's EPS will be -$1.10 for 2025, with the lowest EPS forecast at -$1.25, and the highest EPS forecast at -$0.94. On average, analysts forecast that GLSI's EPS will be -$1.48 for 2026, with the lowest EPS forecast at -$1.48, and the highest EPS forecast at -$1.48. In 2027, GLSI's EPS is forecast to hit -$1.47 (min: -$1.47, max: -$1.47).

What is GLSI's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: GLSI) forecast ROE is 3,768.58%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.